POST Online Media Lite Edition


Tesaro announces election of Garry Nicholson to board

Staff writer |
Waltham, Mass., USA - May 15, 2015, Waltham, Mass., USA - Tesaro, Inc., an oncology-focused biopharmaceutical company, announced that Garry A. Nicholson has been elected to the Tesaro board of directors.

Article continues below

Mr. Nicholson has 20 years of experience in oncology drug development and commercialization. He most recently served as President, Pfizer Oncology, from May 2008 until March 2015.

As the first leader of Pfizer's global, dedicated oncology business, Mr. Nicholson had direct responsibility for business strategy and operations, including the oncology sales and marketing organizations globally, clinical development for both early and late stage pipeline candidates, and for licensing and acquisitions.

Prior to joining Pfizer, Mr. Nicholson worked at Eli Lilly and Company in a number of leadership roles, including sales management, marketing, human resources, sales and marketing, and oncology drug development.

LATEST 5 MOVES FROM Massachusetts 

What to read next

F2G appoints Ian Nicholson as CEO
James B. Nicholson joins PrivateBancorp's board of directors
Tesaro appoints Joseph L. Farmer as senior vice president